• Not yet recruiting

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Modakafusp alfa (Formerly TAK-573)

Modakafusp Alfa

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma


The main aims of this study is to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.

Sponsor:

Takeda

 

ClinicalTrials.gov Identifier: NCT05556616

Official Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

First Posted : September 27, 2022

Click here to see details on ClinicalTrials.gov

 

Drug: Modakafusp alfa

Drug: Lenalidomide

Drug: Bortezomib

Drug: Carfilzomib

Drug: Daratumumab

Drug: Pomalidomide

 

TAK-573

Modakafusp Alfa (Code C140427)

Anti-CD38-targeted IgG4-attenuated IFNa TAK-573

Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573

CD38-targeted IgG4 Fused with Attenuated IFNa

Modakafusp Alfa

MODAKAFUSP ALFA

TAK-573

 

Locations

United States, Arkansas

United States, California

United States, Colorado

United States, Florida

United States, Iowa

United States, Kansas

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Nevada

United States, New York

United States, North Carolina

United States, Ohio

United States, Pennsylvania

United States, Tennessee

United States, Texas

Canada, Ontario

Canada, Quebec

Europe

Asia

Austria

Belgium

Israel

Italy

Spain

United Kingdom




Posts Archive